What are the differences between amphetamine and methylphenidate for treating ADHD, including indications, dosing, efficacy, side effects, and monitoring?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Amphetamine vs Methylphenidate for ADHD

For children and adolescents (ages 6-17), methylphenidate should be the preferred first-line stimulant, while for adults, amphetamines demonstrate superior efficacy and should be the first choice. This recommendation is based on the most comprehensive network meta-analysis showing age-specific differences in comparative effectiveness 1.

Age-Specific First-Line Recommendations

Children and Adolescents (6-17 years)

  • Start with methylphenidate as the preferred stimulant 1
  • Initial dose: 5 mg twice daily (before breakfast and lunch) 2
  • Titrate by 5-10 mg weekly based on response 3, 2
  • Maximum dose: 60 mg/day 2

Rationale: While both medications are effective, methylphenidate shows a more favorable benefit-risk profile in pediatric populations. The 2018 Lancet network meta-analysis of 10,068 children found methylphenidate superior to placebo with clinician ratings (SMD -0.78) and teacher ratings (SMD -0.82), with better tolerability than amphetamines in this age group 1.

Adults (18+ years)

  • Start with amphetamines as the preferred stimulant 1
  • Dose range: 12-26 mg/day (optimal net clinical benefit at 18-20 mg/day) 4
  • Maximum dose varies by formulation

Rationale: Amphetamines demonstrate significantly greater efficacy in adults (SMD -0.79) compared to methylphenidate (SMD -0.49) 1. The 2026 dose-response analysis confirmed amphetamines achieve higher maximal net clinical benefit in adults, even after accounting for adverse event-related discontinuation 4.

Comparative Efficacy

Direct Comparison Data

Head-to-head comparisons favor amphetamines over methylphenidate in both age groups for symptom reduction:

  • Children/adolescents: SMD difference of -0.24 to -0.46 favoring amphetamines 1
  • Adults: SMD difference of -0.29 to -0.94 favoring amphetamines 1
  • A 2010 meta-analysis found amphetamines moderately more efficacious than methylphenidate across all ages, with effect sizes remaining significant after controlling for study design 5

However, the clinical significance of this difference must be weighed against tolerability, particularly in children where methylphenidate's safety profile is more favorable.

Optimal Dosing Ranges

Methylphenidate

  • Children/adolescents: Efficacy plateaus at approximately 45 mg/day 4, 6
  • Adults: Efficacy continues increasing without clear plateau (limited data at higher doses) 6
  • Therapeutic blood concentration: 7.2-11.3 ng/mL (IQR) or 1.1-16.6 ng/mL (mean±SD) 7

Amphetamines (d-amphetamine)

  • Children/adolescents: Efficacy plateaus at approximately 25 mg/day 4, 6
  • Adults: Efficacy plateaus above 50 mg/day 6
  • Therapeutic blood concentration: 18.4-32.5 ng/mL (IQR) or 16.6-47.1 ng/mL (mean±SD) 7

Tolerability and Safety Differences

Discontinuation Due to Adverse Events

Amphetamines show higher discontinuation rates:

  • Children/adolescents: OR 2.30 vs placebo 1
  • Adults: OR 3.26 vs placebo 1
  • Risk increases above 25 mg/day in children and 50 mg/day in adults 6

Methylphenidate shows better tolerability in children:

  • Children/adolescents: No significant difference from placebo 1
  • Adults: OR 2.39 vs placebo 1
  • Risk increases above 50 mg/day in adults 6

Weight Effects

Amphetamines cause greater weight loss, particularly in the first 3 months:

  • Mean weight loss at 3 months: -1.44 kg (amphetamine) vs -0.31 kg (methylphenidate), p=0.005 8
  • This is a critical consideration for underweight children or those with growth concerns

Common Adverse Effects (Both Medications)

Per FDA labeling 2:

  • Tachycardia and palpitations
  • Insomnia and anxiety
  • Decreased appetite
  • Headache
  • Abdominal pain

Guideline-Based Treatment Algorithm

Step 1: Pre-Treatment Assessment 3, 2

Screen for contraindications:

  • Cardiac disease: Obtain careful history, family history of sudden death/ventricular arrhythmia, physical exam
  • Psychiatric comorbidities: Screen for anxiety, depression, bipolar disorder, psychosis
  • Tics/Tourette's syndrome: Assess family history and clinical evaluation
  • Glaucoma: Evaluate patients with significant hyperopia
  • MAOI use: Contraindicated within 14 days

Step 2: Age-Based First-Line Selection

  • Ages 6-17: Start methylphenidate 3, 1
  • Ages 18+: Start amphetamines 1

Step 3: Titration Protocol 3, 2

  • Start low and increase weekly
  • Monitor with validated rating scales (e.g., IOWA Conners for school-based assessment)
  • Titrate to maximum benefit with tolerable side effects
  • Do not exceed doses where efficacy plateaus: 45 mg/day for methylphenidate and 25 mg/day for amphetamines in children 4, 6

Step 4: Switching Medications

Switch from first-line to alternative stimulant if:

  • Inadequate response after reaching optimal dose range
  • Intolerable side effects
  • Specific concerns (e.g., excessive weight loss with amphetamines)

Persistence data: At 12 months, 68% remained on methylphenidate vs 56% on amphetamines (not statistically significant, p=0.15), suggesting comparable real-world acceptability 8.

Critical Pitfalls to Avoid

  1. Therapeutic inertia: Do not accept suboptimal response without titrating to effective doses within the plateau range 6

  2. Uncritical dose escalation: Avoid exceeding doses where efficacy plateaus, as harms increase without additional benefit 4, 6

  3. Ignoring age-specific differences: The superior efficacy of amphetamines in adults does not translate to a better benefit-risk profile in children 1

  4. Inadequate monitoring: Both medications require monitoring of:

    • Blood pressure and heart rate 2
    • Growth parameters in children (height and weight) 3, 2
    • Psychiatric symptoms (new-onset psychosis, mania, aggression) 2
    • Signs of abuse or diversion 2
  5. Missing cardiac screening: Both medications carry risks in patients with structural cardiac abnormalities, cardiomyopathy, or serious arrhythmias 2

Abuse Potential and Storage

Both medications are Schedule II controlled substances with high abuse potential 2. Before prescribing:

  • Assess each patient's risk for abuse, misuse, and addiction
  • Educate patients and families about proper storage (preferably locked) and disposal
  • Monitor throughout treatment for signs of diversion or substance use disorder
  • Recognize that misuse can result in overdose and death, particularly with unapproved routes (snorting, injection)

Monitoring Requirements

Initial Phase (First 3 Months)

  • Weekly symptom ratings during titration 3
  • Vital signs at each visit
  • Weight monitoring (especially with amphetamines) 8

Maintenance Phase

  • Regular follow-up per chronic care model 3
  • Periodic assessment of continued need and dose optimization
  • Growth monitoring in children (may need treatment interruption if not growing as expected) 3, 2
  • Screen for emergence of tics, psychiatric symptoms, or cardiovascular concerns

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.